Quality of Life in Lymphoma Patients One Year Post-chemotherapy

Quality of Life in Lymphoma Patients and Cancer Care Pathway One Year Post-chemotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04187118

Acronym

QUALIPSO-L

Enrollment

600

Registered

2019-12-05

Start date

2020-01-28

Completion date

2025-06-30

Last updated

2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

Lymphoma, Quality Of Life, Cancer Care Pathway, Post-Chemotherapy

Brief summary

Malignant lymphomas are considered as among the most chemo-sensitive cancers. ML are cured in more than 85% of patient, the majority with complete response. After this active phase of treatment, patients are in after cancer period. Toulouse University Hospital developed since 2006 the Ambulatory Medical Assistance for After Cancer program on lymphoma patient. Ambulatory Medical Assistance for After Cancer is very efficient for detecting physical and psychological complications which impact quality of life. The investigators identified 22% of lymphoma patients who had a reduced quality of life one year after the end of chemotherapy. The present study aims to investigate the evolution of observed complications and identify cancer care pathway which decrease the quality of life reduction risk in patients one year after lymphoma chemotherapy.

Detailed description

Quality of life, as well anxiety, depression, social isolation, fear of cancer recurrence, post traumatic stress, will be measured in lymphoma patients, after a first line chemotherapy. Care cancer pathway will be also evaluated. Self-administered questionnaires will be performed on website (www.hospitalidee.fr) after inclusion and 12 months after.

Interventions

OTHERQuality of life

Quality of life one year post chemo-therapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients being in complete response after a first therapy for lymphoma * Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation * Patients informed of the study and not opposed to the research

Exclusion criteria

* Patients under legal guardian . * Patients unavailable to formulate non-opposition to the study

Design outcomes

Primary

Measure	Time frame	Description
Quality of life change: Quality of Life-C30 French version	Change from baseline quality of life at 12 month	Health-related quality of life is evaluated by the use of Quality of Life-C30 French version

Countries

France

Contacts

Primary ContactLoïc YSEBAERT, MD, PhD

ysebaert.loic@iuct-oncopole.fr561145940

Backup ContactFabien DESPAS, Pharm, PhD

fabien.despas@univ-tlse3.fr561145940

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026